-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Cytokinetics, Raises Price Target to $105

Benzinga·11/05/2026 21:55:13
Listen to the news
Citigroup analyst Eric Joseph maintains Cytokinetics (NASDAQ:CYTK) with a Buy and raises the price target from $99 to $105.